Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency

Joseph A. Church, Heinz Leibl, Mark R. Stein, Isaac R. Melamed, Arye Rubinstein, Lynda C. Schneider, Richard L. Wasserman, Borislava G. Pavlova, Karl Birthistle, Marianne Mancini, Sandor Fritsch, Lisa Patrone, Kerry Moore-Perry, Hartmut J. Ehrlich, Joseph A. Church, Linda B. Ford, Roger H. Kobayashi, Dennis K. Ledford, Issac R. Melamed, James N. MoyArye Rubinstein, Lynda C. Schneider, Mark R. Stein, Dale T. Umetsu, Richard L. Wasserman

Research output: Contribution to journalArticle

62 Scopus citations

Abstract

The present clinical study was designed to evaluate the efficacy, pharmacokinetics and safety of a new 10% liquid intravenous immune globulin in patients with primary immunodeficiency diseases. Sixty-one adults and children with primary immuno-deficiency diseases received doses of 300-600 mg/kg body weight every 21-28 days for 12 months. No validated acute serious bacterial infections were reported. The 95% confidence interval for the annualized rate of acute serious bacterial infections (primary endpoint) was 0-0.060. A total of four predefined validated other bacterial infections commonly occurring in primary immunodeficiency disease subjects were observed; none were serious, severe or resulted in hospitalization. The median elimination half-life of IgG was 35 days. Median total IgG trough levels varied from 9.6 to 11.2 g/L. Temporally associated adverse experiences were determined for 72 h after each infusion and the most common adverse experience was headache, which was associated with 6.9% of infusions. The study met the primary endpoint for efficacy and demonstrated excellent tolerability of the new 10% liquid intravenous imunoglobulin preparation.

Original languageEnglish (US)
Pages (from-to)388-395
Number of pages8
JournalJournal of Clinical Immunology
Volume26
Issue number4
DOIs
StatePublished - Jul 1 2006

Keywords

  • Efficacy
  • IGIV
  • Immune globulin
  • Pharmacokinetics
  • Primary immunodeficiency
  • Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency'. Together they form a unique fingerprint.

  • Cite this

    Church, J. A., Leibl, H., Stein, M. R., Melamed, I. R., Rubinstein, A., Schneider, L. C., Wasserman, R. L., Pavlova, B. G., Birthistle, K., Mancini, M., Fritsch, S., Patrone, L., Moore-Perry, K., Ehrlich, H. J., Church, J. A., Ford, L. B., Kobayashi, R. H., Ledford, D. K., Melamed, I. R., ... Wasserman, R. L. (2006). Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. Journal of Clinical Immunology, 26(4), 388-395. https://doi.org/10.1007/s10875-006-9025-3